Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Prevention of Diabetes Mellitus Development in Women Who Had Already Experienced A Gestational Diabetes
- Conditions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Medical University of Lodz
- Registration Number
- NCT00265746
ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity
- Conditions
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT00263965
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2005-12-08
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 389
- Registration Number
- NCT00263276
- Locations
- 🇵🇷
Local Institution, San Juan, Puerto Rico
🇨🇦Local institution, Bathurst, New Brunswick, Canada
🇺🇸Local Insitution, Edina, Minnesota, United States
GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate
- Conditions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00261352
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
GALLANT 8 Tesaglitazar Add-on to Metformin
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 555
- Registration Number
- NCT00251953
- Locations
- 🇬🇧
Research Site, Wrexham, United Kingdom
Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)
- Conditions
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2006-10-09
- Lead Sponsor
- Kaplan Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT00247117
- Locations
- 🇮🇱
Institute of Endocrinology, Kaplan Medical Center, Rehovot, Israel
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 58
- Registration Number
- NCT00232583
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 320
- Registration Number
- NCT00191464
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico
Impact of Genetics on Metformin Pharmacokinetics
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 24
- Registration Number
- NCT00187798
- Locations
- 🇺🇸
University of California San Francsico, San Francisco, California, United States
Genetic Basis for Variation in the Renal Elimination of Metformin
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 23
- Registration Number
- NCT00187720
- Locations
- 🇺🇸
San Francisco General Hospital, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.